INTRODUCTION 1
The RAS-RAF-MEK-ERK signaling pathway is activated in many human tumors, including those 2 with BRAF, RAS and NF1 mutations and some with activated growth factor receptors. The pathway has 3 been shown to play a role in driving proliferation, suppressing apoptosis and in mediating other aspects of 4 the transformed phenotype and is thought to be necessary for the maintenance of the growth and viability 5 of many tumors (1) . This has led to efforts to develop inhibitors of components of this pathway as 6 antitumor agents (2). Recently, inhibitors of the MEK and RAF kinases have met with some success in the 7 treatment of melanomas with V600E or V600K BRAF mutations (3, 4, 5). RAF inhibitors only inhibit ERK 8 signaling in cells with activating mutation of BRAF and activate ERK signaling in other cells (6, 7). They 9 therefore have a wide therapeutic index and remarkable activity in melanoma patients with mutant BRAF, 10 but clearly cannot be effective in tumors with mutant RAS due to paradoxical activation of RAF (7, 8, 9) . 11 MEK inhibitors have significant activity in patients with mutant BRAF melanoma (3), and some activity in 12 patients with RAS mutant tumors (10, 11, 12). However, the ability of MEK inhibitors to potently inhibit 13 ERK signaling may be limited by their toxicity and by relief of ERK dependent-feedback inhibition of RAF, 14 which causes induction of MEK phosphorylation (13). 15
MATERIALS AND METHODS 1

Recombinant proteins and cell lines 2
For RAF biochemical enzyme assays, MEK1 K97R (C-terminally His 6 tagged full length MEK1 with K97R 3 mutation, Millipore), B-RAF wt (N-terminally GST-His 6 -thrombin cleavage site fused to BRAF 417-766, 4
ProQinase), B-RAF V600E (N-terminally GST-His 6 -thrombin cleavage site fused to BRAF 417-766 with a 5 V600E mutation, ProQinase), Raf-1 (N-terminally GST-tagged Raf-1 306-end with mutations Y340D and 6 Y341D, Millipore) were used. For MEK biochemical assays, MEK1 S218E/S222E (N-terminally His 6 fused 7 full length MEK1 with S218E and S222E mutations) and MAP Kinase 2/Erk 2 (N-terminally His 6 fused full 8 length full length mouse MAP Kinase 2/Erk2, Millipore) were used. For biophysical analysis, N-terminally 9
His 6 tagged unphosphorylated full length wild-type MEK1 kinase 
(MAP2K1 (MEK1) Recombinant 10
Human Protein, P3093) and N-terminally GST-fused phosphorylated full length wild-type MEK1 kinase 11
(1-393) (MAP2K1, 07-141) were purchased from Invitrogen and Carna Bioscience respectively. 12 N-terminally GST-fused BRAF kinase domain (433-726) (GST-BRAF), N-terminal GST-tagged CRAF 13 kinase domain (306-648) Y340D/Y341D (GST-CRAF) and N-terminal GST-tagged BRAF kinase domain 14 (433-726) with V600E mutation (GST-BRAF V600E) were purchased from Carna Bioscience (BRAF 15 (09-112) , RAF1 (09-125) and BRAF [V600E], respectively). All cell lines except for human leukemic 16
(5-Fl-SGQLIDSMANSFV-NH 2 , MEKtide) by using the IMAP fluorescence polarization (FP) Screening 1
Express Kit (Molecular Devices). 2
Inhibition of MEK1 was evaluated by a coupled assay with active MEK1 (MEK1 S218E/S222E, 3 ProQinase) and unactive dephosphorylated ERK2 (MAP Kinase 2/Erk 2, Millipore). The phosphorylation 4 of a fluorescent labeled peptide substrate (FAM-Erktide, IPTTPITTTYFFFK-5FAM-COOH) by ERK2 was 5 quantified by using the IMAP FP Screening Express Kit (Molecular Devices). 6 7
Surface plasmon resonance (SPR) 8
All of the biosensor experiments were conducted on the Biacore 2000 or Biacore T100 systems (GE 9
Healthcare) at 15ºC with a flow rate of 30 µL/min. For direct binding experiments of test compounds to 10 MEK, His 6 -MEK1 was minimally biotinylated with sulfo-NHS-LC-LC biotin (Thermo Scientific), and then 11 coupled to a streptavidin-coated sensor chip (GE Healthcare). Solutions of test compounds were injected 12 over the surface for one minute or two minutes and then the flow was switched to a running buffer: 13
Tris-based saline (50 mM tris(hyroxyethyl)carboxymethane-HCl, pH 7.6, 150 mM NaCl, 10 mM MgCl 2 , 1 14 mM dithiothreitol (DTT), 0.01% P-20, and 1% dimethyl sulfoxide (DMSO)). 15
For direct binding assays of test compounds to RAF, N-terminal GST tagged BRAF or CRAF was 16 captured on the surface of a CM5 sensor chip (GE Healthcare) by anti-GST polyclonal antibodies that 17 were pre-immobilized on the chip according to the manufacturer's instructions. Then, 10 μM of test 18 compound solutions in 1% DMSO were injected over the prepared sensor chip. Phosphate-based saline(10 mM phosphate, pH 7.4, 138 mM NaCl, 2.7 mM KCl, 10 mM MgCl 2 , 1 mM DTT, 0.01% P-20, and 1% 1 DMSO) was used as a running buffer. 2
The effects of CH5126766 and PD0325901 on the BRAF-or CRAF-MEK1 interactions were determined 3 using single-cycle kinetics due to the slow dissociation of His 6 -MEK1 from RAF. In these experiments, 4
His 6 -MEK1 solutions at concentrations of 0.0256, 0.064, 0.16, 0.4 and 1 μM, were injected sequentially in 5 order of increasing concentration over the sensor chip in the absence or presence of 3 μM of the test 6 compounds and then the dissociation constants of His 6 -MEK1 were calculated for the immobilized BRAF 7 or CRAF for each condition. In these experiments, 500 μM ATP was added to the running buffer. 8
The resulting sensorgrams were double-referenced, DMSO-calibrated, and fitted to determine kinetic 9 parameters by using SCRUBBER2 (BioLogics), BIAevaluation ver3.1, T100 evaluation ver2.0 or or T200 10 evaluation ver1.0 (GE Healthcare) software. 11 12
Co-immunoprecipitation of MEK1 and BRAF 13
The 293H cells transfected with 2 μg FLAG-tagged full length ARAF, BRAF, CRAF or BRAF V600E 14 plasmid DNA (8) or HCT116 cells were treated with 0.1% DMSO or MEK inhibitors (50 nM PD0325901 or 15 250 nM CH5126766 in 0.1% DMSO) for 1 h (293H transfected cells) or 2 hours (HCT116 cells). Cells 16 were lysed in 1% NP40 lysis buffer (50 mM Tris pH 7.5, 150 nM NaCl, 10% glycerol and 1 mM EDTA) 17 supplemented with 2.5 mM sodium orthovanadate, 10 mM PMSF and protease inhibitor cocktail (EMD). 18
For immunoprecipitation of FLAG-tagged RAF proteins, agarose conjugated anti-FLAG antibody beadsand on the first day of treatment, respectively, for the experimental groups and likewise, where C and C0 1 were the mean tumor volumes for the control group. The value of the 50% effective dose (ED 50 ) for each 2 compound was calculated based on the formula for the straight line that connected the two points for 3 which y was equal to 50%. Each treatment group included 4 to 6 animals. Statistical . 1A ) was obtained by iterative rounds of derivatization of a hit 3 compound from a cell-based high-throughput screen for compounds that induce expression of the cell 4 cycle inhibitor p27
Kip1 in tumor cells. CH5126766 induced p27 Kip1 protein expression and caused G1 5 arrest in a human lung large cell carcinoma cell line NCI-H460 (KRAS Q61H) and two colorectal 6 adenocarcinoma cell lines, HT29 (BRAF V600E) and HCT116 (KRAS G13D) ( Supplementary Fig. S1A  7 and S1B). We attempted to determine the target of the drug by using the COMPARE drug screening 8 algorithm (14), which analyzes the pattern of anti-proliferative activity obtained in a panel of tumor cell 9 lines exposed to different agents. Among the 21 antitumor agents tested, including CH5126766, 10 anti-metabolites (5-fluorouracil, gemcitabine and methotrexate), a DNA damaging agent (cisplatin), a DNA 11 intercalator (doxorubicin), an alkylating agent (mytomycin C) and inhibitors of MEK (CI-1040, PD0325901 12 and AZD6244), EGFR (erlotinib), Bcr-Abl (imatinib and dasatinib), multiple kinases (sorafenib and 13 sunitinib), HSP90 (geldanamycin), proteasome (bortezomib), mTOR (rapamycin), PI3K (LY294002), 14 topoisomerase I (camptotecin) and microtubules (paclitaxel), only MEK inhibitors were associated with a 15 pattern of inhibition similar to that obtained with CH5126766 (correlation coefficients greater than 0.8, 16
Supplementary Table S1) . 17
MEK is a component of the cascade of kinases responsible for the activation of ERK signaling. 18
To determine whether the effects of the drug were due to inhibition of MEK or RAF, we assessed itseffects on their catalytic activity in cell-free kinase assays (Fig. 1B) Table S2) . 9
In order to examine whether the drug also inhibits these targets in cells, we investigated the 10 effect of CH5126766 on phosphorylation of MEK and ERK in tumor cells. HCT116 KRAS mutant 11 colorectal cancer cells were treated with CH5126766 for 2 h, and the phosphorylation status of MEK and 12 ERK were analyzed. As shown in Figure 1C , CH5126766 reduced the levels of phospho-MEK and 13 phospho-ERK to undetectable levels, whereas other MEK inhibitors PD0325901 and GSK1120212 only 14 inhibited ERK phosphorylation. When HCT116 cells were treated with either of two RAF inhibitors 15 (GDC-0879 and PLX-4720), phosphorylation of MEK and ERK were induced as previously reported in 16 response to paradoxical activation of RAF kinase (Fig. 1C) . Thus, the effects of CH5126766 on ERK 17 signaling in HCT116 were different from those of both MEK inhibitors and RAF inhibitors. 18
The effects of CH5126766 on ERK signaling were further assessed in a panel of tumor cells with oras a function of genotype (RAS/RAF wt, BRAF V600E mutant, mutant RAS) and compared with those 1 obtained with PD0325901. In tumors with RAS mutation, CH5126766 effectively inhibited both MEK and 2 ERK phosphorylation (Fig. 1D) . This differs from the effects of PD0325901, which inhibited ERK 3 phosphorylation and induced MEK phosphorylation in these cells (Fig. 1D) . CH5126766 also inhibited 4 MEK and ERK phosphorylation in mutant BRAF tumors as well as WT RAS/BRAF cells whereas the MEK 5 inhibitor PD0325901 inhibited ERK phosphorylation in these cells and had no apparent effect on MEK 6 phosphorylation ( Fig. 1D) . Thus, the effects of CH5126766 on ERK signaling in tumor cells and in cell 7 free kinase assays differ from those obtained with other inhibitors of RAF or MEK and are consistent with 8 finding that it inhibits both kinases in vitro assays. 9
Mechanism of inhibition of MEK and ERK phosphorylation 11
It seemed unlikely, however, that the effects of CH5126766 are due to its selective and 12 independent binding to two kinases, RAF and MEK, one of which is required for the activation of the other. 13
We therefore utilized surface plasmon resonance (SPR) analyses to assess whether CH5126766 binds 14 directly to MEK, BRAF or CRAF. Our SPR analyses with immobilized His 6 -MEK1 showed that both 15 CH5126766 and PD0325901 bind to His 6 -MEK1 (Fig. 2) . In the presence of 50 µM ATP, the binding signal 16 of CH5126766 or PD0325901 to His 6 -MEK1 was additive with that obtained with ATP alone. These data 17 suggest that CH5126766 does not compete with ATP for binding to His 6 -MEK, but that instead it binds to 18 another site in the protein. This is consistent with our data that the K D s of CH5126766 for His 6 -MEK1 aresimilar in the presence or absence of 50 µM ATP (16 nM and 6.1 nM, respectively). Moreover, the binding 1 signal obtained with His 6 -MEK1 in the presence of 0.2 µM CH5126766 and 0.2 µM PD0325901 was not 2 additive with that obtained with 0.2 µM PD0325901 alone in our SPR analysis (Fig. 2) . Thus, we conclude 3 that CH5126766 binds to the known site of binding (15) of the allosteric inhibitors MEK inhibitors, such as 4 PD0325901. In our biochemical MEK kinase assay, CH5126766 did not inhibit the kinase activity of 5 phosphorylated GST-MEK1 on S218 and S222 (Supplementary Fig. S3 ). This suggests that 6 phosphorylation of S218 and S222 is critical for the affinity of CH5126777 for MEK1. This is consistent 7 with the previous observations that this region is important for MEK1 binding of other allosteric MEK 8
inhibitors (16). 9
By contrast, SPR analyses revealed no evidence for binding of CH5126766 to immobilized 10 GST-BRAF or GST-CRAF (Fig. 3A) . These data suggest that the inhibition of His 6 -MEK1 K97R 11 phosphorylation by CH5126766 (Fig. 1B) is not due to a direct interaction of the drug with RAF kinases. 12 Indeed, when a peptide substrate for RAF (MEKtide, corresponding to human MEK1 212-224 and human 13 MEK2 217-229 (SGQLIDSMANSFV-NH 2 )) was substituted for the MEK1 protein as the substrate in an in 14 vitro assay of CRAF kinase activity, CH5126766 did not affect the peptide phosphorylation 15 (Supplementary Fig. S2 ). Given these data, we concluded our initial evidence that CH5126766 bound to 16 Table S2 ) was an artifact of the extremely 17 high concentration (10 µM) of drug employed in this assay compared to the much lower concentrations of 18 drug required to inhibit MEK phosphorylation in cells (~0.01 µM, Fig. 1C ).
RAF proteins in the KINOMEscan profiling (Supplementary
These results suggested the hypothesis that CH5126766 inhibits RAF kinase by binding to MEK1. 1
To test this idea, we used SPR to determine whether the drug alters the interaction between RAF and 2 MEK. CH5126766 decreased the dissociation rate of His 6 -MEK1 from GST-BRAF ( Fig. 3B and  3 Supplementary Table S4 ). We observed similar effects when we substituted GST-CRAF for GST-BRAF. 4
In contrast, PD0325901 had no effect on the kinetics of dissociation of this protein complex. Moreover, 5
co-immunoprecipitation analysis with lysates of 293H cells engineered to express FLAG-tagged RAF 6 proteins showed that CH5126766 causes MEK1/2 to interact with all three FLAG-tagged RAF proteins, 7
including FLAG-tagged BRAF V600E, whereas PD0325901 causes MEK1/2 to interact with FLAG-tagged 8 wild type ARAF and CRAF, but not FLAG-tagged wild type BRAF and mutant BRAF (Fig. 3C ). Whereas 9 considerable MEK2 was immunoprecipitated with each of the FLAG-RAF from lysates of cells treated with 10 CH5126766, the relative amount of MEK1 pulled down with FLAG-wild type BRAF was much greater 11 than that pulled down with FLAG-CRAF or FLAG-BRAF V600E. Whether this reflects differences in 12 affinity of MEK1 and MEK2 to the different RAF proteins has not yet been addressed. Similar results were 13 obtained when we used KRAS mutated HCT116 cells and immunoprecipitated endogenous BRAF. In the 14 cells treated with CH5126766, MEK and CRAF were co-immunoprecipitated with BRAF, whereas in the 15 DMSO or PD0325901 treated cells, only CRAF was co-immunoprecipitated with BRAF (Fig. 3D) . The 16 results suggest that CH5126766-bound MEK binds to and inhibits RAF kinase activity. To assess this 17 possibility, the ability of CRAF to phosphorylate the MEKtide in an in vitro kinase assay was evaluated in 18 the presence or absence of unphosphorylated His 6 -MEK1 proteins and MEK or RAF inhibitors (Fig. 3E) .
The pan-RAF inhibitor PLX4720 inhibited CRAF activity whether or not His 6 -MEK1 was present and 1 PD0325901 did not inhibit the phosphorylation of the MEKtide by CRAF kinase in either circumstance. In 2 contrast, CH5126766 inhibited CRAF activity in a His 6 -MEK1-dependent manner (Fig. 3E) . Moreover, the 3 inhibition of CRAF activity by CH5126766 was dependent on the concentration of His 6 -MEK1. These 4 results suggest that binding of CH5126766 to MEK causes MEK to bind to and inhibit RAF and inhibit its 5 kinase activity. Taken together, the data suggest a model in which the drug binds to MEK and causes it to 6 adopt a conformation in which it binds to RAF, but cannot be phosphorylated by and released from RAF. 7
As a consequence, CH5126766 causes MEK to become a dominant negative inhibitor of RAF. ERK signaling output at similar degrees in the tumors from the drug-treated mice at 4 h from the first drug 1 administration (Fig. 4B) . Moreover, in HCT116 models, the 50% effective dose of tumor growth inhibition 2 (ED 50 ) for CH5126766 and PD0325901 were 0.056 mg/kg and 0.80 mg/kg, respectively (Supplementary 3 Fig. S3) . Therefore, the doses used for this experiment were 26.8-fold and 31.3-fold higher doses than 4 the 50% effective doses, respectively. As shown in Figure 4A , daily oral administration of either drug 5 caused significant tumor regression of each these tumors. However, whereas inhibition of tumor growth 6 was maintained for the entire 28-day treatment period in CH5126766-treated mice, tumor models 7 receiving PD0325901 became refractory after 10 days of treatment. We observed similar differences 8 between CH5126766 and PD0325901 in Calu-6, an anaplastic lung carcinoma model with Q61K mutant 9 KRAS, but not in COLO205, a colorectal adenocarcinoma model with V600E mutant BRAF (Fig. 5A) . 10
To assess whether differences in the extent of ERK pathway inhibition could account for the 11 difference in efficacy of the two drugs, the tumors in Figure 4A were resected 4 h after the first dose or 4 12 h after the last of 34 days of daily dosing of the drug. In the PD0325901-treated tumors, MEK was highly 13 phosphorylated (Fig. 4B) . Although pMEK was induced by PD0325901 treatment, this was not associated 14 with an increased ERK phosphorylation, which was undetectable in tumors treated with either drug even 
multiple dosing. These differences were not observed 4 h after the initial dose of these inhibitors. Similar 1 effects were observed in CH5126766-treated Calu-6 tumors with Q61K KRAS, whereas no downstream 2 activation of ERK signaling was noted in PD0325901-treated COLO205 tumors with V600E BRAF even 3 after multiple dosing (Fig. 5B) . The results suggest that CH5126766 is a more effective inhibitor of ERK 4 signaling output than PD0325901 in chronically treated tumors with RAS mutations. 5
We also examined whether the refractory tumors from the PD0325901-treated mice would 6 respond to CH5126766. The tumors that became refractory to PD0325901 were treated daily with either 7 PD0325901 or CH5126766. As shown in Figure 4C , the growth of the refractory tumors ceased in the 8 CH5126766-treated group but continued to increase in the PD0325901-treated group. These data 9 suggest the resistance of these tumors is secondary to the modest rebound in ERK signaling noted in 10 PD0325901-treated tumors and that the more prolonged growth inhibition with CH5126766 is due to more 11 effective inhibition of the pathway. 
DISCUSSION 1
The elevation of ERK output in tumors with RAS or BRAF mutation and the sensitivity of such 2 tumors to inhibitors of components of the pathway suggest that this may be a useful therapeutic strategy. 3
RAF inhibitors
melanomas with V600E BRAF mutation but they cannot be used to treat tumors in which the pathway is 8 driven by other oncoproteins. Of note, antitumor activity in tumors with mutant BRAF requires very 9 substantial (greater than 80%) inhibition of ERK output (18). 10
As opposed to RAF inhibitors, MEK inhibitors inhibit ERK signaling in all normal and tumor cells. 11
They can therefore be used to treat RAS tumors. However, these drugs have only marginal therapeutic 12 effects in patients with these tumors (10, 11, 12). RAS has been shown to activate more than ten effectors 13 in model systems, of which three-RAF, PI3K, RAL-GDS-have been most strongly shown to mediate 14 is conceivable that phosphorylation of these sites (MEK S218 and S222) by RAF could reduce inhibition 7 of MEK activity by the drug and reduce maximal inhibition of ERK (28), but this has not been 8
demonstrated. This idea is consistent with our observations that feedback reactivation of RAF by 9 conventional allosteric MEK inhibitors is more pronounced in cells with activated RAS in cells with mutant 10
BRAF mutants or wild type RAS and BRAF (Fig. 1D) (17) . 11
We now report the generation of a novel allosteric MEK inhibitor, CH5126766, that does not 12 cause induction of MEK phosphorylation, despite its potent inhibition of ERK phosphorylation. This 13 compound and PD0325901 compete for binding to the same site on MEK1 (Fig.2) to which they bind with 14 similar affinity (K D s for CH5126766 and PD0325901: 4.5 nM and 19 nM, respectively, Supplementary 15 Table S3 ). Both inhibitors block ERK phosphorylation and signaling in cells. However, as opposed to 16 (Fig. 1C &1D) , a result that suggests that it directly inhibits RAF activity. This turns out to be the case, but 18 only when full length MEK is present in the RAF kinase assay. Furthermore, the drug does not directlybind to RAF (Fig. 3A) . 1 The effects of the drug are explained by the demonstration that it causes MEK to bind to RAF. In 2 this complex, the drug-bound MEK is not phosphorylated and its dissociation rate from RAF is much 3 reduced compared to that of unbound MEK or MEK bound to PD0325901 (Fig. 3B, 3C & 3D) . The 4 dissociation of MEK protein from immobilized RAF protein was retarded by CH5126766: k off value was 5 changed with a two order magnitude difference from 1.48 x 10 -2 to 2.76 x 10 -4 (BRAF-MEK1) and from 6 1.58 x 10 -2 to 1.62 x 10 -4 (CRAF-MEK1) by adding CH5126766. But it had no effect on the association of 7 MEK with RAF: k on value was almost unchanged from 2.25 x 10 5 to 1.2 x 10 5 (BRAF-MEK1) and from 3.46 8
x 10 5 to 2.39 x 10 5 (CRAF-MEK1) by adding CH5126766 (Supplementary Table S4 ). Thus, MEK bound 9 to CH5126766 is a dominant negative inhibitor of RAF. This is consistent with a model in which the 10 binding of the drug to MEK causes the latter to adopt a conformation in which it cannot be phosphorylated 11 by RAF. 12 CH5126766 preferentially binds to non-phosphorylated MEK1 rather than phosphorylated MEK1 13 in our cell free MEK kinase assay (Supplementary Fig. S3 ). Our current data strongly suggests that 14 CH5126766 only binds to the unphosphorylated enzyme, inhibits it and prevents its phosphorylation. It 15 does not inhibit the phosphorylated enzyme well, but rather traps the unphosphorylated enzyme so it 16 cannot be phosphorylated. This is why the affinity for the unphosphorylated enzyme is high (KINOMEscan 17 and SPR assays) and the drug is a potent inhibitor of MEK phosphorylation (RAF kinase in cells) but a 18 less potent inhibitor of phosphorylated MEK in a kinase assay (Fig. 1B) . Since the co-immunoprecipitatedMEK proteins with RAF proteins were not phosphorylated (Fig. 3C) , it was suggested that 1 phosphorylation of MEK causes its dissociation from RAF. From these lines of evidence, we speculate 2 that the drug binds selectively to the non-phosphorylated form of MEK, locks it into the unphosphorylated 3 conformation, and stabilizes MEK-RAF complex, The RAF/MEK drug bound complex is inactive and 4 stable, thus the drug suppresses the feedback induction of MEK phosphorylation that occurs after ERK 5 pathway inhibition in tumors exposed to other MEK inhibitors (Fig. 1C & 1D) . 6
The cellular effects of CH5126766 thus appear to be those of a combined MEK and RAF inhibitor. 7
Despite inhibition of RAF by CH5126766, it does not induce paradoxical activation of RAF kinases in cells 8
in which active RAF is a dimer because it does not bind to RAF directly. 9
Since CH5126766 suppresses induction of MEK phosphorylation, it can be used to determine 10 whether feedback reactivation of RAF reduces ERK inhibition by inhibitors such as PD0325901. Indeed, 11 CH5126766 effectively inhibited ERK phosphorylation in vivo in RAS mutant xenografts and was a more 12 potent inhibitor of ERK output and tumor growth than PD0325901 (Fig. 4 & Fig. 5 ). These data suggest 13 but do not prove that preventing induction of pMEK accounts for the greater efficacy of this drug. 14 GSK1120212 (trametinib, JTP-74057), another MEK inhibitor, has significant therapeutic efficacy 15 in patients with melanomas with BRAF V600E or V600K mutation (3) as well as in some RAS tumors (10). 16 case, picking compounds that induced p15 expression (29, 30).This agent binds to the same site in MEK 18 proteins as PD0325901 with higher affinity to MEK1 than PD0325901 (30) and induces phosphorylation ofS222 but not S218 MEK1. In KRAS mutated cells, however, phosphorylation of MEK S222 was increased 1 although phosphorylation of S218 MEK1 was prevented (16). It is possible that the significant clinical 2 activity of this drug is due in part to partial suppression of feedback reactivation of ERK. As a class, such 3 MEK inhibitors may offer the chance for enhanced pathway output inhibition and antitumor activity without 4 necessarily increasing toxicity. 5
In the phase I clinical investigation of CH5126766, two partial responses in BRAF V600E 6 melanoma and in one Q61K NRAS mutated melanoma patient was reported (12). However, the long 7 plasma half-life of CH5126766 in human (60 h), and its continuous daily dosing were associated with a 8 severe rash (12). Further progress in the use of the drugs to potently inhibit ERK signaling in tumors will 9 require identification of the optimal doses and administration schedules in order to maximize inhibition of 10 signaling and antitumor activity without unacceptable toxicity. 11
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